Aging colon shows a programmed loss of ZO‑1 and occludin that precedes measurable DNA damage or oxidative injury. This pattern matches the timing of systemic NAD+ decline, suggesting that the cell interprets low NAD+ as a cue to downgrade energetically costly processes. We hypothesize that reduced NAD+ limits SIRT1 deacetylase activity in intestinal epithelial cells, leading to hyperacetylation and repression of transcription factors that normally drive Tjp1 and Tjp2 expression. Specifically, SIRT1 normally deacetylates FOXO3, allowing it to bind promoters of tight‑ junction genes and sustain their transcription. When NAD+ falls, FOXO3 remains acetylated, loses DNA affinity, and TJ gene expression drops. The resulting barrier leak permits microbial products to trigger low‑grade inflammation, which further consumes NAD+ via CD38 activation, creating a feed‑forward loop that locks the epithelium into a low‑maintenance state.

This hypothesis makes several testable predictions. First, pharmacological or genetic restoration of NAD+ specifically in the colonic epithelium of aged mice should rescue FOXO3 deacetylation, restore ZO‑1 and occludin levels, and reduce serum LPS without altering global NAD+ levels in other tissues. Second, intestinal‑epithelial‑specific SIRT1 knockout in young mice will recapitulate the aged TJ phenotype—decreased Tjp1/Tjp2 mRNA, mislocalized proteins, and increased permeability—even when NAD+ is abundant. Third, acetate‑mimic mutations that force FOXO3 into an acetylated state will suppress TJ expression irrespective of NAD+ or SIRT1 status, while deacetylation‑mimic FOXO3 will maintain barrier integrity in old animals despite NAD+ scarcity. Fourth, blocking CD38 to break the inflammation‑NAD+ consumption loop should slow the progressive decline of TJ proteins during aging, indicating that the loop amplifies but does not initiate the program.

Experiments to test these predictions are straightforward. Use Villin‑CreERT2;Sirt1fl/fl mice induced at 3 months, measure TJ protein expression and colonic permeability at 6 and 12 months, and compare to littermate controls treated with NAD+ precursors (NR or NMN) delivered via colon‑targeted nanoparticles. Parallel assays will quantify FOXO3 acetylation (immunoprecipitation followed by Western blot) and chromatin occupancy at Tjp1/Tjp2 promoters (ChIP‑qPCR). Serum LPS, IL‑6, and TNF‑α will serve as functional readouts of barrier failure and inflammaging. If NAD+ restoration fails to rescue TJ expression when FOXO3 remains acetylated, or if SIRT1 loss mimics aging regardless of NAD+, the hypothesis is supported. Conversely, if NAD+ supplementation fully restores barrier function without affecting FOXO3 acetylation or SIRT1 activity, the model would be falsified, pointing to alternative NAD+‑dependent mechanisms.

By framing TJ downregulation as a metabolically gated transcriptional program rather than cumulative damage, this hypothesis shifts the focus from passive decay to active resource allocation. It explains why barrier loss is evolutionarily conserved, why it tracks NAD+ decline, and why interventions that boost NAD+ can ameliorate inflammaging—provided they reach the epithelial niche and engage the SIRT1‑FOXO3 axis.